DETAIL
■この商品は「予約販売商品」です
・この商品はコンビニ払いがご利用できません。
・Erler-Zimmer GmbH & Co.KG（ドイツ）で受注生産のため、納期は4〜6カ月かかります。
・ご注文いただいた後、入荷時期が確定いたしましたら、正式にメールにてご連絡申し上げます。
拡大した前立腺を横方向にスライスして外側と切断面を表示したものです。切断面には直径 2 〜 10 mm のさまざまな大きさの結節が多数あります。これは前立腺の良性結節過形成 (BPH) の例です。
Product information "Nodular hyperplasia of the Prostate"
Clinical History
A 63-year old male presented to the emergency departed with acute abdominal pain. He has been unable to pass urine for 5 days. Further questioning revealed a 2-year history of urinary frequency, double void, urinary hesitancy, nocturia and a poor urine stream. Abdominal examination showed a tender distended bladder and an enlarged palpable prostate on digital rectal examination. A bedside bladder scan demonstrated a volume of >1L in the bladder. Blood tests shows a severe acute kidney injury. He is diagnosed with acute renal failure due to acute urinary retention. There were multiple failed attempts at catheterising the patient via the urethra and suprapublically. A total prostatectomy was performed and he made a good recovery.
Pathology
The specimen is an enlarged prostate gland sliced transversely to display the external and cut surfaces, On the cut surface there are numerous nodules varying in size from 2-10mm in diameter. This is an example of benign nodular hyperplasia (BPH) of the prostate gland.
Note
Benign prostatic hyperplasia (BPH) or nodular hyperplasia of the prostate is a common disease in older men. BPH is caused by nodular hyperplasia of prostatic stromal and glandular epithelial cells primarily in the periurethral prostate. Hyperplasia is a result of accumulation of senescent cells due to impaired cell death and cell proliferation driven by androgens, mainly dihydrotesterone. Disproportionate enlargement of the median lobe is a common feature of nodular hyperplasia of the prostate. The projecting median lobe may occlude the internal urethral orifice on contraction of the bladder.
Prevalence of BPH increases significantly with age. BPH is present in 20% of males at 40 years of age, 70% of males of 60 year of age and almost 90% of males by the age of 80. There is an increased risk of BPH in men with a positive family history of BPH, in obese males and exposure to exogenous androgenic-anabolic steroids.
Clinical presentation of BPH results from urinary obstructive symptoms. Patients complain of urinary frequency, nocturia, urinary hesitancy, double voiding, poor urinary stream and overflow dribbling. Acute urinary retention may result from complete urinary tract obstruction as in the case discussed above. Post void residual urine results from the obstructing prostate which leads to an increased risk of urinary tract infections.
Diagnosis can be made on clinical history and physical examination of the prostate with a digital rectal exam. Prostate specific antigen may be used to screen for prostate cancer. Ultrasound scan or CT can be used to evaluate the volume of the prostate. Treatment of BPH can be treated medically with Alpha-blockers to relax the prostate smooth muscle tone or 5-alpha-reductase inhibitors, which inhibit synthesis of dihydrotesterone. The main surgical treatment for severe cases of BPH is transurethral resection of the prostate (TURP). Total prostatectomy is no longer used due to risk of disabling complications.
●京都科学品番：EZ-310 ●メーカー品番：MP2108
Erler-Zimmer GmbH & Co.KG の模型製品は、
日本国内において株式会社京都科学の独占販売製品です。
